Joaquin Duato

Chairman of the Board and CEO at Johnson & Johnson

Board

Since January 3, 2022

Age

61 years

Education

Holds an MBA from ESADE in Barcelona, Spain and a Master of International Management from Thunderbird School of Global Management in Phoenix, Arizona.

Tenure

Joined the company in 1989 and advanced through multiple leadership roles—including positions as Worldwide Chairman of Pharmaceuticals, Executive Vice President, and Vice Chairman—before becoming CEO on January 03, 2022 and Chairman on January 02, 2023.

Also at Johnson & Johnson

Elizabeth Forminard

EVP, General Counsel

James Swanson

EVP, Chief Information Officer

JLT

Jennifer L. Taubert

EVP, Worldwide Chairman, Innovative Medicine

About

Joaquin Duato is a globally minded leader known for his dual citizenship in Spain and the United States, which has enriched his international perspective and commitment to diverse viewpoints. His personal approach is deeply rooted in the company’s Credo values, emphasizing patient care, employee well-being, and community responsibility.

Throughout a distinguished career spanning over 35 years at the organization, he has consistently taken on roles of escalating responsibility. His career highlights include key positions in the Pharmaceuticals sector, where he provided strategic guidance and operational leadership during his tenure as Worldwide Chairman, Executive Vice President, and Vice Chairman.

Under his visionary leadership, the strategic direction of the company has been refined with an unwavering focus on innovative medicine and MedTech solutions. His efforts have been pivotal in expanding the pipeline of therapies in critical areas such as oncology, immunology, neuroscience, and pulmonary hypertension, reinforcing his reputation as a purpose-driven executive.

$JNJ Performance Under Joaquin Duato

Past Roles

Organization	Role	Date Range	Details
Hess Corporation	Director	2019 - 2022	Former external board role
Johnson & Johnson	Vice Chairman of the Executive Committee	July 2018 - 2022?	Provided strategic direction for Pharmaceutical and Consumer Health sectors, supply chain, IT, global services, and Health & Wellness groups
Johnson & Johnson	Executive Vice President, Worldwide Chairman, Pharmaceuticals	2016
Johnson & Johnson	Member of the Executive Committee	2016
Johnson & Johnson	Worldwide Chairman, Pharmaceuticals	2011
Johnson & Johnson	Company Group Chairman, Pharmaceuticals	2009

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$1,584,615	Annual	Fixed base pay.
Registrant Contributions to Defined Contribution Plans	$71,308	Annual	Contribution to defined contribution plans.
Insurance Premiums	$0	Annual	No insurance premium expense.
Perquisites and Other Personal Benefits	$170,684	Annual	Includes $145,685 for personal use of corporate aircraft and personal use of a company car and driver.

Performance Compensation

Data from FY 2023

Annual Incentive Payout

Metric (Unit, scale)	Value with Citation
Threshold (USD)	$0
Target (USD)	$2,800,000
Maximum (USD)	$5,600,000
Actual Payout (USD)	$3,650,000
Financial Goals Weight (%)	70%
Strategic Goals Weight (%)	30%
Enterprise Financial Payout Factor (%)	130.5%
Enterprise Strategic Payout Factor (%)	130.0%
Overall Payout Factor (%)	130.4%
Performance Period	Calendar Year 2023
Payout Timing	Q1 2024

Long-Term Incentives (LTIs)

Component (Unit, scale)	Details
PSUs	Grant Date: Feb 13, 2023; Vesting Schedule: 3-year period with 0% to 200% outcome; Performance Metrics: EPS (50% weight) and Relative TSR (50% weight); Grant Date Fair Value: Target $9,335,592 and Maximum $18,671,185.
RSUs	Grant Date: Feb 13, 2023; Vesting Schedule: One-third vests per anniversary over 3 years; Grant Date Fair Value: $1,599,051.
Options	Grant Date: Feb 13, 2023; Vesting Schedule: One-third per year with a 10-year term; Exercise/Base Price: $162.75 per share; Grant Date Fair Value: $4,796,990.

Annual Performance Bonus

Metric (Unit, scale)	Details
Performance Metrics	Based on combined financial (70% weight) and strategic (30% weight) goals.
Overall Payout Factor	130.4% of target, with a payout range from 0% to 200% of the target award.
Evaluation & Vesting	Aligned with the performance review of the Annual Incentive Payout; evaluated for the calendar year 2023 with cash-based award mechanics.

This comprehensive performance compensation structure for 2023 includes multiple components with clearly defined metrics, targets, vesting schedules, and actual outcomes as detailed above.